Valneva IPO Presentation Deck

VLA2001's Inactivated Virus Technology Allows for Potential Differentiation H 81 VLA2001 - an inactivated, adjuvanted COVID- 19 vaccine candidate... ■ Only COVID-19 vaccine candidate in clinical trials in Europe using inactivated virus technology, an approach that is well established ■ Potential to be used as booster vaccine in all age groups ■ Potential ease of storage and distribution (expected 2 to 8°C) ■ Potential platform for new variants ...with a clear go to market strategy V ■ 100M doses contract signed with UK government for 2021-2022 Discussions with other potential customers ongoing ■ Initiated process with potential US partners to evaluate entering the US market ■ Manufacturing track record and FDA/EMA/MHRA approved facilities

View entire presentation